65,437 trials
Plaque Psoriasis · Psoriatic Arthritis
Primary: Number of Participants Reporting Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) and AEs of Special Interests (AESIs) From Week 0 to Week 24…
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer
Primary: Change in Tumor SUVmax Assessed by 18F-FLT PET Imaging — -0.39 SUVmax — p=0.087
Metastatic Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8
Primary: Maximal Tolerated Dose (MTD) of Siltuximab That Can be Combined With Spartalizumab — 11 mg/kg
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -20.7; -18.5; -24.0; -17.8 Score on a scale — p=0.241
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
Endometrial Diseases · Pain, Postoperative
Primary: Pain After Endometrial Biopsy, as Measured by Visual Analogue Scale (VAS) — 50; 60 mm — p=0.039
HIV · Medication Adherence
Primary: Tel-me-box Adherence — 10; 16.5; 1.5; 7 days (out of 30)
Fecal Incontinence
Primary: Primary Effectiveness Endpoint — 75.9 percentage of treatment responders
Frailty
Primary: Feasibility, Measured as Acceptance Rate — 20 Participants
Spinal Cord Injury
Primary: Urethral Sphincter Pressure — 50 cmH2O
Suicide Prevention
Primary: Suicidal Ideation: The Beck Scale for Suicidal Ideation (BSS) — 2.0; 10.7 units on a scale
Pregnancy Related · Stress, Psychological · Glucose Intolerance During Pregnancy
Primary: Postprandial Glycemic Response With Stress Exposure — 12998.83; 12833.69 mg/dl * minutes
Corneal Erosion
Primary: Change From Baseline to Week 12 in Total Corneal Fluorescein Staining — -2.55; -0.37 units on a scale
Stroke, Ischemic · Motor Activity · Upper Extremity Paralysis
Primary: Mean Change in FM-UE From Baseline — 4.91; 3.87; 5.53 units on a scale — p=0.39